Open access · OA
via Europe PMC
Thioredoxin-2 Alleviates Osteoporosis by Restraining FOXO3a Nuclear Translocation.
Zhan C, Zhou Z, Ding Y, Lian R, Li X, Zhang X, Cao J, Tang Z, Lin Z, Song Z, He F.
Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
Abstract
Osteoporosis is a prevalent age- and disease-associated skeletal disorder characterized by bone loss, remodeling imbalance, and vascular niche deterioration, yet how endothelial redox dysfunction drives this process remains unclear. Here, we identify mitochondrial thioredoxin-2 (TRX2) as an endothelial safeguard against osteoporotic bone loss. TRX2 was markedly reduced in aging bone vascular endothelial cells, and endothelial Trx2 deficiency accelerated skeletal degeneration by suppressing osteogenic activity and enhancing osteoclastogenesis. Mechanistically, TRX2 directly bound FOXO3a through a redox-sensitive Cys90-Cys31 disulfide interaction, retaining FOXO3a at the mitochondrial outer membrane and limiting its nuclear translocation. TRX2 loss or oxidative stress disrupted this complex, enabling FOXO3a-dependent transcriptional activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and generating a pro-osteoclastogenic vascular niche. TRAIL neutralization or endothelial TRX2 restoration attenuated ovariectomy-induced osteoporosis by preserving angiogenic-osteogenic coupling. These findings establish the endothelial TRX2-FOXO3a-TRAIL axis as a vascular redox checkpoint and potential therapeutic target for osteoporosis.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- Europe PMC
- DOI
- 10.1002/advs.78304
- Canonical
- link ↗
- Fetched
- 2026-10-21 MST
Cite this
APA
C, Z., Z, Z., Y, D., R, L., X, L., X, Z., J, C., Z, T., Z, L., Z, S., & F., H. (2026). Thioredoxin-2 Alleviates Osteoporosis by Restraining FOXO3a Nuclear Translocation. <em>Advanced science (Weinheim, Baden-Wurttemberg, Germany)</em>. https://doi.org/10.1002/advs.78304
Vancouver
C Z, Z Z, Y D, R L, X L, X Z, et al. Thioredoxin-2 Alleviates Osteoporosis by Restraining FOXO3a Nuclear Translocation. Advanced science (Weinheim, Baden-Wurttemberg, Germany). 2026. doi:10.1002/advs.78304.
BibTeX
@article{zhan2026Thiore,
title = {Thioredoxin-2 Alleviates Osteoporosis by Restraining FOXO3a Nuclear Translocation.},
author = {Zhan C and Zhou Z and Ding Y and Lian R and Li X and Zhang X and Cao J and Tang Z and Lin Z and Song Z and He F.},
journal = {Advanced science (Weinheim, Baden-Wurttemberg, Germany)},
year = {2026},
doi = {10.1002/advs.78304},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Theranostics 2026
Open access · CC-BY
ARG2 drives osteoblast senescence by repressing mitophagy via the IκB–NF-κB–TXN2 signaling axis: implications for age-associated osteoporosis
The Journal of clinical investigation
Open access · OA
Deconstructing senescence phenotypes in cells of the bone and bone marrow
Elsevier eBooks 2021
Citation only
Osteoporosis and bone loss
Aging Cell 2025
Open access · CC-BY
Senescent Cells Involved in Deterioration of Bone Microstructure by High‐Frequency Parathyroid Hormone 1–34 Administration and Bone Loss
Antioxidants (Basel, Switzerland) 2026
Open access · OA
Sirtuin-1 in Hypertension: Linking Oxidative Stress and Mitochondrial Dysfunction to Vascular Aging and Therapeutic Potential.
Aging Cell 2024
Open access · CC-BY